Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Lululemon Athletica Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.74 (market cap $4.49B), while Lululemon Athletica Inc trades at $114.03 (market cap $13.13B). The key difference: Lululemon Athletica Inc is far larger — about 2.9× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | LULU | |
|---|---|---|
Market Cap | $4.49B | $13.13B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $238.54 |
52-Week Low | $20.06 | $105.43 |
Enterprise Value | $3.69B | $13.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
LULU trades at $115.07, down 2.84% for the day, reflecting recent bearish sentiment amid a 45% year-to-date decline. The stock is near its pivot point of $115, with technical indicators signaling a bearish trend. Fundamentally, the company reported strong revenue of $10.59B in 2025 and a net income margin of 17.13%, with a low P/E of 9.36 suggesting undervaluation. Recent news highlights board settlement with founder Chip Wilson but also cultural missteps in China and a class-action lawsuit over tariff costs.
The outlook is mixed: attractive valuation and international growth potential contrast with North American weakness and brand reputation risks. Analyst consensus is a $130.53 price target with 41% buy ratings, but near-term volatility persists. Key risks include execution on guidance, competitive pressures, and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
